Table 1.
Baseline demographics and clinical characteristics of patients with chronic idiopathic constipation
| Baseline demographics and clinical characteristics | Overall (N = 690) | Patients aged 18–64 yr (n = 634) | Patients aged ≥65 yr (n = 56) |
| Age, yr, mean (SD) | 48.0 (14.7) | 45.7 (12.8) | 74.4 (7.1) |
| Sex, n (%) | |||
| Female | 604 (87.5) | 563 (88.8) | 41 (73.2) |
| Male | 86 (12.5) | 71 (11.2) | 15 (26.8) |
| Charlson Comorbidity Index,a mean (SD) | 0.5 (1.0) | 0.5 (1.0) | 1.1 (1.5) |
| Initial dose of prucalopride, mg, mean (SD) | 1.9 (0.3) | 1.9 (0.3) | 1.8 (0.4) |
| 1.0 mg, n (%) | 76 (11.0) | 66 (10.4) | 10 (17.9) |
| 2.0 mg, n (%) | 614 (89.0) | 568 (89.6) | 46 (82.1) |
| Any constipation-related comparator treatment any time before the index date,b n (%) | 436 (63.2) | 399 (62.9) | 37 (66.1) |
| Index drugs,c n (%) | |||
| Prucalopride monotherapy | 507 (73.5) | 464 (73.2) | 43 (76.8) |
| Prucalopride combination therapy | 183 (26.5) | 170 (26.8) | 13 (23.2) |
| Prucalopride and lubiprostone | 26 (3.8) | 24 (3.8) | 2 (3.6) |
| Prucalopride and linaclotide | 118 (17.1) | 110 (17.4) | 8 (14.3) |
| Prucalopride and plecanatide | 28 (4.1) | 26 (4.1) | 2 (3.6) |
| Prucalopride and >1 other constipation-related prescription medication | 11 (1.6) | 10 (1.6) | 1 (1.8) |
a
The Charlson Comorbidity Index was defined based on criteria by Charlson et al (21) and adapted by Quan et al (22).
b
The index date was defined as the first prucalopride prescription fill date. Constipation-related comparator medications included lubiprostone, linaclotide, or plecanatide.
c
Constipation-related prescription medications taken concurrently with the index drug included lubiprostone, linaclotide, or plecanatide.